NZ597222A - Substituted 8-[6-Amino-3-Pyridyl]Xanthines - Google Patents
Substituted 8-[6-Amino-3-Pyridyl]XanthinesInfo
- Publication number
- NZ597222A NZ597222A NZ597222A NZ59722207A NZ597222A NZ 597222 A NZ597222 A NZ 597222A NZ 597222 A NZ597222 A NZ 597222A NZ 59722207 A NZ59722207 A NZ 59722207A NZ 597222 A NZ597222 A NZ 597222A
- Authority
- NZ
- New Zealand
- Prior art keywords
- pyridyl
- propyl
- cyclopropyl
- amino
- xanthine
- Prior art date
Links
- DIVYESOURJTWDY-UHFFFAOYSA-N 8-(6-aminopyridin-3-yl)-3,7-dihydropurine-2,6-dione Chemical class C1=NC(N)=CC=C1C(N1)=NC2=C1C(=O)NC(=O)N2 DIVYESOURJTWDY-UHFFFAOYSA-N 0.000 title abstract 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000026935 allergic disease Diseases 0.000 abstract 2
- 229940075420 xanthine Drugs 0.000 abstract 2
- -1 1-cyclopropyl Chemical group 0.000 abstract 1
- 108050000203 Adenosine receptors Proteins 0.000 abstract 1
- 102000009346 Adenosine receptors Human genes 0.000 abstract 1
- 101150078577 Adora2b gene Proteins 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- XLHBCJMUAJETQC-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-n-(2-piperidin-1-ylethyl)-6-(trifluoromethyl)pyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CCN3CCCCC3)C(=O)C=3C=NC(=CC=3)C(F)(F)F)NC=2C(=O)N1C1CC1 XLHBCJMUAJETQC-UHFFFAOYSA-N 0.000 abstract 1
- ZDGGEBFIUSOGIG-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-n-(cyclopropylmethyl)-6-fluoropyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CC3CC3)C(=O)C=3C=NC(F)=CC=3)NC=2C(=O)N1C1CC1 ZDGGEBFIUSOGIG-UHFFFAOYSA-N 0.000 abstract 1
- IKIXRBGOWUFFBN-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-n-methyl-6-(trifluoromethyl)pyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(C)C(=O)C=3C=NC(=CC=3)C(F)(F)F)NC=2C(=O)N1C1CC1 IKIXRBGOWUFFBN-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80503006P | 2006-06-16 | 2006-06-16 | |
| US80556406P | 2006-06-22 | 2006-06-22 | |
| US11/811,823 US7884100B2 (en) | 2006-06-16 | 2007-06-12 | Substituted 8-[6-amino-3-pyridyl]xanthines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ597222A true NZ597222A (en) | 2013-06-28 |
Family
ID=56290980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ597222A NZ597222A (en) | 2006-06-16 | 2007-06-13 | Substituted 8-[6-Amino-3-Pyridyl]Xanthines |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7884100B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2029143B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5417558B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101413404B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103145712A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007261568B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0712001B8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2655598C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2029143T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA016791B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2548437T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE026457T2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL195916A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2008015954A (cg-RX-API-DMAC7.html) |
| MY (1) | MY152178A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ597222A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2029143T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2029143E (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| EP1658291B1 (en) * | 2003-08-25 | 2013-10-02 | Dogwood Pharmaceuticals, Inc. | Substituted 8-heteroaryl xanthines |
| US7618962B2 (en) * | 2005-02-25 | 2009-11-17 | Pgx Health, Llc | Pyrazolyl substituted xanthines |
| US7598379B2 (en) | 2005-02-25 | 2009-10-06 | Pgx Health, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
| WO2006091897A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Derivatives of 8-substituted xanthines |
| US7884100B2 (en) | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
| US7875608B2 (en) * | 2007-12-17 | 2011-01-25 | Thompson Robert D | Substituted 8-[6-amino-3pyridyl]xanthines |
| BR112023023996A2 (pt) * | 2021-05-18 | 2024-01-30 | Adovate Llc | Xantinas de piridil contendo amida cíclica como antagonistas de a2b |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| US6060481A (en) * | 1998-05-28 | 2000-05-09 | The Penn State Research Foundation | Method for improving insulin sensitivity using an adenosine receptor antagonist |
| GB9817623D0 (en) * | 1998-08-13 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| AU2001238342A1 (en) * | 2000-02-17 | 2001-08-27 | Cv Therapeutics, Inc. | Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation |
| US7304070B2 (en) | 2001-11-09 | 2007-12-04 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| KR100937620B1 (ko) * | 2001-11-09 | 2010-01-20 | 씨브이 쎄러퓨틱스, 인코포레이티드 | Ａ２ｂ 아데노신 수용체 길항제 |
| US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US6977300B2 (en) * | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| NZ528591A (en) * | 2002-02-01 | 2006-11-30 | King Pharmaceuticals Res & Dev | 8-heteroaryl xanthine adenosine A2B receptor antagonists and their pharmaceutical use |
| US7034070B2 (en) * | 2002-09-27 | 2006-04-25 | Vincent Chuang | Arylalkyl aminofunctional silanes for epoxy laminates |
| US7148229B2 (en) * | 2003-02-19 | 2006-12-12 | Hoffman-La Roche Inc. | Sulfonamide substituted xanthine derivatives |
| EP1658291B1 (en) * | 2003-08-25 | 2013-10-02 | Dogwood Pharmaceuticals, Inc. | Substituted 8-heteroaryl xanthines |
| KR101247528B1 (ko) | 2004-09-01 | 2013-04-15 | 길리애드 사이언시즈, 인코포레이티드 | Ａ２ｂ 아데노신 수용체 길항제를 사용하는 상처 치유 방법 |
| WO2006028840A2 (en) | 2004-09-03 | 2006-03-16 | United States Postal Service | Methods and systems for providing an enterprise supply management portal |
| CN101039677A (zh) * | 2004-10-15 | 2007-09-19 | Cv医药有限公司 | 利用a2b腺苷受体拮抗剂预防和治疗气道重建及肺部炎症的方法 |
| WO2006091897A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Derivatives of 8-substituted xanthines |
| US7598379B2 (en) * | 2005-02-25 | 2009-10-06 | Pgx Health, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
| US7618962B2 (en) * | 2005-02-25 | 2009-11-17 | Pgx Health, Llc | Pyrazolyl substituted xanthines |
| US7601723B2 (en) * | 2005-02-25 | 2009-10-13 | Pgx Health, Llc | Pyridyl substituted xanthines |
| US7625881B2 (en) * | 2005-06-16 | 2009-12-01 | Gilead Palo Alto, Inc. | Prodrugs of A2B adenosine receptor antagonists |
| JP5250848B2 (ja) * | 2006-03-17 | 2013-07-31 | ギリアード サイエンシーズ， インコーポレイテッド | Ａ２ｂアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法 |
| AU2006344750A1 (en) * | 2006-06-15 | 2007-12-27 | Targeted Genetics Corporation | Methods for treating target joints in inflammatory arthritis using AAV vectors encoding a TNF antagonist |
| US7884100B2 (en) | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
| US7767685B2 (en) * | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
| US7875608B2 (en) * | 2007-12-17 | 2011-01-25 | Thompson Robert D | Substituted 8-[6-amino-3pyridyl]xanthines |
| CA2718983C (en) * | 2008-03-26 | 2015-12-08 | Advinus Therapeutics Pvt. Ltd. | Heterocyclic compounds as adenosine receptor antagonist |
-
2007
- 2007-06-12 US US11/811,823 patent/US7884100B2/en not_active Expired - Fee Related
- 2007-06-13 KR KR1020097000879A patent/KR101413404B1/ko active Active
- 2007-06-13 NZ NZ597222A patent/NZ597222A/xx unknown
- 2007-06-13 MX MX2008015954A patent/MX2008015954A/es active IP Right Grant
- 2007-06-13 AU AU2007261568A patent/AU2007261568B2/en active Active
- 2007-06-13 PT PT77960490T patent/PT2029143E/pt unknown
- 2007-06-13 PL PL07796049T patent/PL2029143T3/pl unknown
- 2007-06-13 ES ES07796049.0T patent/ES2548437T3/es active Active
- 2007-06-13 JP JP2009515468A patent/JP5417558B2/ja not_active Expired - Fee Related
- 2007-06-13 EP EP07796049.0A patent/EP2029143B1/en active Active
- 2007-06-13 BR BRPI0712001A patent/BRPI0712001B8/pt active IP Right Grant
- 2007-06-13 MY MYPI20084937 patent/MY152178A/en unknown
- 2007-06-13 CA CA2655598A patent/CA2655598C/en active Active
- 2007-06-13 CN CN2013100513402A patent/CN103145712A/zh active Pending
- 2007-06-13 HU HUE07796049A patent/HUE026457T2/en unknown
- 2007-06-13 EA EA200900010A patent/EA016791B1/ru unknown
- 2007-06-13 DK DK07796049.0T patent/DK2029143T3/en active
-
2008
- 2008-12-14 IL IL195916A patent/IL195916A/en active IP Right Grant
-
2010
- 2010-12-14 US US12/967,876 patent/US8258142B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2008015954A (es) | 2009-03-06 |
| EA200900010A1 (ru) | 2009-10-30 |
| MY152178A (en) | 2014-08-15 |
| JP2010500284A (ja) | 2010-01-07 |
| US20110082139A1 (en) | 2011-04-07 |
| IL195916A0 (en) | 2009-09-01 |
| BRPI0712001A2 (pt) | 2012-01-10 |
| CA2655598A1 (en) | 2007-12-27 |
| KR101413404B1 (ko) | 2014-06-27 |
| DK2029143T3 (en) | 2015-09-21 |
| US7884100B2 (en) | 2011-02-08 |
| US20080004292A1 (en) | 2008-01-03 |
| HUE026457T2 (en) | 2016-05-30 |
| KR20090029268A (ko) | 2009-03-20 |
| JP5417558B2 (ja) | 2014-02-19 |
| PT2029143E (pt) | 2015-10-20 |
| EP2029143A2 (en) | 2009-03-04 |
| AU2007261568A1 (en) | 2007-12-27 |
| BRPI0712001B1 (pt) | 2020-04-07 |
| CA2655598C (en) | 2014-10-28 |
| EP2029143A4 (en) | 2009-07-15 |
| BRPI0712001B8 (pt) | 2021-05-25 |
| US8258142B2 (en) | 2012-09-04 |
| IL195916A (en) | 2015-06-30 |
| ES2548437T3 (es) | 2015-10-16 |
| EP2029143B1 (en) | 2015-07-08 |
| AU2007261568B2 (en) | 2013-05-16 |
| EA016791B1 (ru) | 2012-07-30 |
| CN103145712A (zh) | 2013-06-12 |
| PL2029143T3 (pl) | 2015-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ597222A (en) | Substituted 8-[6-Amino-3-Pyridyl]Xanthines | |
| EP1722798B1 (en) | Pyrimidine compounds as purine receptor antagonists | |
| ES2382154T3 (es) | Derivados de triazolo [4,5-D]piramidina y su uso como antagonistas de los receptores de purina | |
| EP2170309B1 (en) | 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel | |
| JP4179879B2 (ja) | Ｎ−置換非アリール系複素環ｎｍｄａ／ｎｒ２ｂ拮抗薬 | |
| TWI376378B (en) | Purine compounds | |
| JP7004677B2 (ja) | 動物におけるアレルギー性および／または炎症性疾患の治療および予防に有用な置換インダゾール | |
| EP3253390B1 (en) | Aminoquinazoline compounds as a2a antagonist | |
| MX2007004882A (es) | Derivados de xantina con actividad de receptor de hm74a. | |
| NO20081211L (no) | Xantinderivater som selektive HM74A agonister | |
| HRP20130406T1 (hr) | Medikamenti s aktivnošä†u prema receptoru hm74a | |
| TWI631117B (zh) | 吲哚啉－２－酮衍生物 | |
| WO2005097140A3 (en) | Selective antagonists of a2a adenosine receptors | |
| WO2007103776A3 (en) | A2a adenosine receptor antagonists | |
| JP5667085B2 (ja) | Ａｋｔインヒビターとしての融合されたピリミジン | |
| RS53489B1 (sr) | Jedinjenja i preparati protein kinaznih inhibitora | |
| WO2009158704A3 (en) | Therapeutic agents comprising elastin-like peptides | |
| SG191103A1 (en) | Pyrazole derivative | |
| BG107999A (en) | Imidazolyl derivatives as corticotropin releasing factor inhibitors | |
| Wei et al. | Identification of new potent A1 adenosine receptor antagonists using a multistage virtual screening approach | |
| Suzuki et al. | Discovery and in vitro and in vivo profiles of N-ethyl-N-[2-[3-(5-fluoro-2-pyridinyl)-1H-pyrazol-1-yl] ethyl]-2-(2H-1, 2, 3-triazol-2-yl)-benzamide as a novel class of dual orexin receptor antagonist | |
| ATE519498T1 (de) | Kombination aus somatostatin-analoga unterschiedlicher selektivität für humane somatostatin-rezeptor-subtypen | |
| CA3013569A1 (en) | Pyridine derivative inhibiting raf kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof | |
| Matthee et al. | Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development | |
| ATE388943T1 (de) | Guanidinderivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: FOREST LABORATORIES HOLDINGS LIMITED, BM Free format text: OLD OWNER(S): TROVIS PHARMACEUTICALS LLC |
|
| ASS | Change of ownership |
Owner name: DOGWOOD PHARMACEUTICALS, INC., US Effective date: 20131003 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 13 JUN 2014 BY PIPERS Effective date: 20131111 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 13 JUN 2017 BY PIPERS Effective date: 20140416 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUN 2018 BY COMPUTER PACKAGES INC Effective date: 20170518 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUN 2019 BY COMPUTER PACKAGES INC Effective date: 20180518 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUN 2020 BY COMPUTER PACKAGES INC Effective date: 20190518 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUN 2021 BY COMPUTER PACKAGES INC Effective date: 20200519 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUN 2022 BY COMPUTER PACKAGES INC Effective date: 20210517 |
|
| ASS | Change of ownership |
Owner name: ALLERGAN SALES, LLC, US Effective date: 20210714 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUN 2023 BY THOMSON REUTERS Effective date: 20220502 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUN 2024 BY THOMSON REUTERS Effective date: 20230501 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUN 2025 BY THOMSON REUTERS Effective date: 20240502 |